OptiNose, Inc. (OPTN)
NASDAQ: OPTN · IEX Real-Time Price · USD
1.040
-0.010 (-0.95%)
At close: Jul 2, 2024, 4:00 PM
1.100
+0.060 (5.77%)
After-hours: Jul 2, 2024, 6:28 PM EDT
OptiNose Revenue
OptiNose had revenue of $74.02M in the twelve months ending March 31, 2024, with 0.90% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $14.88M with 25.61% year-over-year growth. In the year 2023, OptiNose had annual revenue of $70.99M, a decrease of -6.93%.
Revenue (ttm)
$74.02M
Revenue Growth
+0.90%
P/S Ratio
2.03
Revenue / Employee
$560,773
Employees
132
Market Cap
150.63M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70.99M | -5.29M | -6.93% |
Dec 31, 2022 | 76.28M | 1.62M | 2.18% |
Dec 31, 2021 | 74.65M | 25.54M | 51.99% |
Dec 31, 2020 | 49.12M | 14.49M | 41.83% |
Dec 31, 2019 | 34.63M | 27.57M | 390.18% |
Dec 31, 2018 | 7.07M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 47.50M | 47.42M | 55,782.35% |
Dec 31, 2015 | 85.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rigel Pharmaceuticals | 120.35M |
Stereotaxis | 27.10M |
Capricor Therapeutics | 27.10M |
ClearPoint Neuro | 26.16M |
Inventiva | 25.74M |
Vaxart | 8.89M |
OPTN News
- 5 days ago - Expanded Access to XHANCE with Addition to National Commercial Formularies - GlobeNewsWire
- 6 weeks ago - Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 7 weeks ago - Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 7 weeks ago - Optinose Announces Reporting Date for First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million - GlobeNewsWire
- 3 months ago - Optinose to Present at the Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - GlobeNewsWire
- 4 months ago - Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights - GlobeNewsWire